---
document_datetime: 2023-09-21 21:22:18
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/glustin-epar-procedural-steps-taken-authorisation_en.pdf
document_name: glustin-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5332051
conversion_datetime: 2025-12-22 00:45:54.955478
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Takeda Europe R &amp; D Centre Limited submitted on 30 March 1999 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Glustin, through the centralised procedure. After agreement by the CPMP on 22 October 1998, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:

<!-- image -->

- A list  of  outstanding  issues  to  be  addressed  in  writing  and  during  an  oral  explanation  by  the Applicant was adopted by the CPMP on 16 March 2000

Rapporteur: Dr. Mary Teeling Co-Rapporteur: Prof. Cristina Sampaio Licensing status: At the time of the application, a new drug application was filed in the following countries: Japan (25 December 1996) and USA (15 January 1999). 2. Steps taken for the assessment of the product · The procedure started on 23 April 1999 · The Rapporteur's first assessment report was circulated to all CPMP Members on 18 June 1999. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 20 June 1999 · During the meeting on 27-29 July 1999 the CPMP agreed on the consolidated list of questions to be sent to the Applicant. The final consolidated list of questions was sent to the Applicant on 28 July 1999 · The Applicant submitted the responses to the CPMP consolidated list of questions on 5 October 1999 · The  summary  report  of the inspection carried out at the manufacturing site between 1-5  November  1999  of  the  Takeda  Chemical  Industries,  Osaka,  Japan,  was  issued  on  21 November 1999 · Supplementary information was provided by the Applicant on 22 November 1999 · The  Rapporteur  and  Co-Rapporteur  circulated  the  joint  response  assessment  report  on  the company's responses to the list of questions to all CPMP Members on 24 November 1999 · The list of outstanding issues to be addressed by the Applicant during an oral explanation was adopted by the CPMP on 16 December 1999 and revised on 15 January 2000 · Written explanations were provided by the Applicant on 14 January 2000 · During  the  CPMP  meeting  on  15  February  2000,  outstanding  issues  were  addressed  by  the Applicant during a oral explanation before the CPMP Medicinal Product no longer authorised

- Written explanations were provided by the Applicant on 9 May 2000
- The Rapporteur circulated a joint assessment report on the company's responses to the list of outstanding issues to all CPMP Members on 15 May 2000
- During  the  CPMP  meeting  on  23  May  2000,  the  outstanding  issues  were  addressed  by  the Applicant  during  an  oral  explanation  before  the  CPMP.  The  adoption  of  the  Opinion  was

<div style=\"page-break-after: always\"></div>

postponed  to  June  2000  CPMP  meeting  in  order  to  further  revise  the  SPC  and  the  postmarketing commitments

- Written explanations were provided by the Applicant on 12 June 2000
- The Rapporteur circulated a joint assessment report on outstanding CPMP issues to all CPMP Members on 19 June 2000
- During the meeting on 27-29 June 2000 the CPMP, in light of the overall data submitted and the scientific  discussion  within  the  Committee,  issued  a  positive  opinion  by majority  vote  for granting a Marketing Authorisation to Glustin on 29 June 2000.

<!-- image -->